Bharat Biotech
-
Malvern-Based Ocugen’s Stock Soars After FDA Lifts Clinical Hold on New Drug Application for COVID Vaccine
Malvern-based Ocugen saw its stock soar after the FDA lifted its clinical hold on the company’s investigational new drug application to test the COVID-19 vaccine…
-
Malvern-based Ocugen Seeks FDA Emergency Use Authorization of Its COVID-19 Vaccine Use in Children
Malvern-based Ocugen has submitted a request to the Food and Drug Administration for Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate for children. The…
-
With Its COVID-19 Vaccine Approved in India, Malvern-Based Biopharma Company Seeks to Start Clinical Trial
Malvern-based Ocugen submitted an investigational new drug application with the FDA. It seeks approval to start a Phase-3 clinical trial that would evaluate the effectiveness…
-
FDA Puts a Snag in Malvern-Based Ocugen’s COVID-19 Vaccine Plans
Malvern-based Ocugen has encountered a significant obstacle in its plans to bring the COVID-19 vaccine developed in India to the U.S., writes John George for…
-
As It Plans a Direct Stock Offering, Malvern-Based Ocugen’s Stock Increases 200-Plus Percent
Malvern-based Ocugen’s stock increased nearly 201 percent after announcing its plans for a direct stock offering worth $23 million, writes John George for the Philadelphia…
-
Malvern-Based Ocugen’s Pandemic Pivot Boosts Its Stock Price by Nearly 800 Percent
The decision to expand beyond gene therapy and sign a deal to co-develop a COVID-19 vaccine has turned out well for Malvern-based Ocugen, writes John…
-
Malvern-Based Ocugen’s Stock Nearly Triples After Inking Pact to Co-Develop COVID-19 Vaccine
Malvern-based Ocugen saw its stock nearly triple last week after the company signed a letter of intent with Bharat Biotech to co-develop the India-based company’s…



















































